MTHFR Support

Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey

4709 Turkish patients with Cardiovascular Disease (CVD) were screened by Oztuzcu et al (2014) over a period of 3 years for the presence of 6 different gene polymorphisms relating to CV health, including Factor 5 Leiden, Prothrombin, Factor 8, MTHFR C677T, A1298C mutations and PAI-1. C677T homozygous and heterozygous mutations were found in 9.34% and 41.09% of patients respectively, with the A1298C homozygous and heterozygous mutations found in 13.78% and 44.94% of patients. Mutations in the PAI-1 gene were found to be of highest prevalence, with MTHFR A1298C and C677T second and third. Of all screened, no genetic mutation was observed in 1.95% of subjects. This research highlights how vital the screening of genetic mutations for the diagnosis and potential treatment of thrombophilia and CVD in this Turkish population.

Article Here

Scroll to Top
Carolyn Ledowsky

Stay Connected!

Sign up for our monthly newsletter with current MTHFR research, health tips, recipes, special offers and news about upcoming events including Carolyn’s live Q&A.